All posts by: SetPoint Medical (Admin)

About SetPoint Medical (Admin)

SetPoint Medical Announces U.S. Pilot Trial to Evaluate First Bioelectronic Device to Treat Rheumatoid Arthritis

  Trial Assesses Proprietary New Device that Delivers Doses of Electricity to Treat Rheumatoid Arthritis; Builds on First-in-Human Data Valencia, CA – March 26, 2018 – SetPoint Medical, a clinical-stage biomedical technology company developing a bioelectronic therapy for chronic inflammatory diseases, today announced it has launched a pilot trial for patients with drug refractory rheumatoid … Continue reading

SetPoint Medical Employees Dedicate Their Day to Hope Gardens

  Valencia, CA – February 15, 2018 – SetPoint Medical, a clinical-stage biomedical technology company developing an implantable bioelectronic medicine therapy for chronic inflammatory diseases, is proud to share the news that 25 SetPoint employees spent the day on Wednesday, February 14 volunteering at Hope Gardens Family Center in Los Angeles. The facility, run by … Continue reading

SetPoint Medical Reports Positive Results from Two Bioelectronic Medicine Studies at North American Neuromodulation Society Meeting

  Company Presented Positive Data on RA 24-Month Follow-up Study and Current Crohn’s Disease Study Valencia, CA – January 14, 2018 – SetPoint Medical, a clinical-stage biomedical technology company developing an implantable bioelectronic medicine therapy for chronic inflammatory diseases, presented positive data from two clinical studies in rheumatoid arthritis (RA) and Crohn’s disease (CD) at … Continue reading

FDA Approves Investigational Device Exemption for SetPoint Bioelectronic Therapy Clinical Study in Rheumatoid Arthritis

  Valencia, CA – December 11, 2017 – SetPoint Medical, a clinical-stage biomedical technology company developing an implantable bioelectronic medicine therapy for chronic inflammatory diseases, has received Investigational Device Exemption (IDE) approval from the U.S. Food & Drug Administration (FDA) to initiate a pilot trial in the U.S. for patients with drug refractory rheumatoid arthritis … Continue reading

SetPoint Medical Presents Early Data Showing Bioelectronic Medicine Accelerates Remyelination in Animal Model of Multiple Sclerosis

  – Data Presented at ECTRIMS-ACTRIMS Multiple Sclerosis Meeting in Paris – Valencia, CA – October 30, 2017 – SetPoint Medical, a clinical-stage biomedical technology company developing a bioelectronic therapy for chronic inflammatory diseases, presented positive data from a study exploring the therapeutic effects of a bioelectronic medicine approach for multiple sclerosis (MS) showing that … Continue reading

SetPoint Secures $30 Million Series D Equity Financing

  – Funding supports clinical momentum; enables upcoming phase 2 trial in rheumatoid arthritis – Valencia, CA – August 28, 2017 – SetPoint Medical, a clinical-stage biomedical technology company developing a bioelectronic therapy for chronic inflammatory diseases, announced today that it has secured $30 million in Series D equity financing. The Series D financing will … Continue reading